OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/EGFR

Lung Cancer — Non-Small Cell (NSCLC)EGFR Clinical Trials

178 recruiting trials·Updated daily from ClinicalTrials.gov

EGFR mutations — primarily exon 19 deletions and exon 21 L858R substitutions — drive tumor growth in about 15% of non-squamous NSCLC in Western populations and up to 50% in East Asian populations. Osimertinib, a third-generation EGFR inhibitor, is the current first-line standard for advanced disease and the approved adjuvant standard after resection (ADAURA). Trials investigate novel EGFR inhibitors, antibody-drug conjugates, and strategies to overcome on-target resistance mutations such as C797S.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting EGFR Lung Cancer — Non-Small Cell (NSCLC) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 3603 US sites

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI)

Phase 377 US sites

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 334 US sites

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

AstraZeneca

Phase 334 US sites

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

AstraZeneca

Phase 2/Phase 328 US sites

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Bristol-Myers Squibb

Phase 312 US sites

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

ArriVent BioPharma, Inc.

Additional trials

More EGFR Lung Cancer — Non-Small Cell (NSCLC) trials

See all in search →

Phase 3

NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/Phase 311 US sites NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/Phase 38 US sites

Phase 2

NCT05642572Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2446 US sites

21 international trials (no US sites)

NCT06486142EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyPhase 3 NCT07182682A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryPhase 3 NCT06829459A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsPhase 3 NCT06670196A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3 NCT06838273A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3 NCT06417008A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerPhase 2/Phase 3 NCT07183189A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCPhase 3 NCT06674343Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsPhase 3 NCT04951635A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerPhase 3 NCT06956001Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationPhase 3 NCT06041776Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsPhase 3 NCT06598527Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective StudyPhase 3 NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCPhase 3 NCT04853342To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyPhase 3 NCT05852990Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLCPhase 3 NCT06908993Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedPhase 3 NCT06031558Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLCPhase 3 NCT07362459A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.Phase 3 NCT06927986Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）Phase 3 NCT07016126D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLCPhase 3 NCT06080776SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsPhase 3

Related therapies

FDA-approved therapies for EGFR Lung Cancer — Non-Small Cell (NSCLC)

Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.

OsimertinibThird-generation EGFR inhibitorEGFR-mutant (ex19del or L858R) NSCLC, first-line and adjuvant AmivantamabEGFR/MET bispecific antibodyEGFR exon 20 insertion NSCLC, after platinum-based chemotherapy (monotherapy, FDA 2021)EGFR del19/L858R or exon 20 insertion NSCLC, first-line, in combination with lazertinib or carboplatin-pemetrexed (FDA 2024)

Other Lung Cancer — Non-Small Cell (NSCLC) biomarkers

Browse other molecular targets with active Lung Cancer — Non-Small Cell (NSCLC) trials.

ALK ROS1 PD-L1 (CD274)KRAS MET HER2 (ERBB2)BRAF RET NTRK1 NTRK2 NTRK3

← All Lung Cancer — Non-Small Cell (NSCLC) clinical trials